Skip to main content
IMS Events Main banner
    22nd International Myeloma Society Annual Meeting

    Poster Discussion

    Friday, September 19, 2025
    12:15 - 13:05 East Coast USA Time
    Location: Room 714A

    Presentations:

    • 12:15 - 12:17 East Coast USA Time
      Introduction
    • 12:17 - 12:23 East Coast USA Time
      (PA-080) Arlocabtagene autoleucel, a GPRC5D-Targeted CAR T-Cell Therapy for Patients With Relapsed/Refractory Multiple Myeloma: Updated Phase 1 Safety and Efficacy Results in Patients With 1–3 Prior Regimens

      Abstract Presenter: Omar Nadeem, MD – Dana-Farber Cancer Institute

    • 12:23 - 12:29 East Coast USA Time
      (PA-517) BCMA CAR-T Therapy with Radiotherapy Bridging and Maintenance Achieves Unprecedented Complete Response in Extramedullary Myeloma

      Abstract Presenter: Lili Zhou, MD & PhD. (she/her/hers) – Shanghai SinoUnited Hospital, China

    • 12:29 - 12:35 East Coast USA Time
      (PA-321) Belantamab Mafodotin plus Lenalidomide/Dexamethasone in Newly Diagnosed Patients with Multiple Myeloma: Long-Term Efficacy and Safety Results from the Phase 1/2 BelaRd Study

      Abstract Presenter: Evangelos Terpos, MD (he/him/his) – Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

    • 12:35 - 12:41 East Coast USA Time
      (PA-199) Elevated Non-Clonal Bone Marrow Plasma Cell Fraction at Diagnosis Is Associated with Improved Outcomes in Multiple Myeloma

      Abstract Presenter: Saurabh Zanwar, MD – Mayo Clinic

    • 12:41 - 12:47 East Coast USA Time
      (PA-034) One-Time Ex-Vivo Conditioning of CAR-T Cells with a Novel Metabolic Modulator

      Abstract Presenter: Taro Hitosugi, PhD – Mayo Clinic

    • 12:47 - 12:53 East Coast USA Time
      (PA-416) Optimizing Belantamab Mafodotin Doses for the Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma in the DREAMM-9 Study

      Abstract Presenter: Karthik Ramasamy, MBBS FRCP FRCPath PhD – University of Oxford and Oxford University Hospitals NHS FT

    • 12:53 - 12:59 East Coast USA Time
      (PA-494) Outcomes in Second-Line Lenalidomide-Refractory Patients in the Phase 3 DREAMM-7 Study of Belantamab Mafodotin, Bortezomib (V), and Dexamethasone (d) vs Daratumumab-Vd in RRMM

      Abstract Presenter: Maria-Victoria Mateos, PhD (she/her/hers) – University Hospital of Salamanca

    • 12:59 - 13:05 East Coast USA Time
      (PA-144) Whole Body Magnetic Resonance Imaging (WBMRI) for Response Evaluation in Patients with Multiple Myeloma

      Abstract Presenter: Ioannis Ntanasis-Stathopoulos, MD (he/him/his) – Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece